Phase 2
Completed N=36
Study of SU11248 in Men With Advanced Prostate Cancer
Source: ClinicalTrials.gov NCT00299741 ↗Enrolled (actual)
36
Serious AEs
69.4%
Results posted
Dec 2012
Primary outcomePrimary: The Number of Men With Advanced Prostate Cancer Treated With Sunitinib Who Have a Prostate Specific Antigen (PSA) Response — 2 participants
Summary
* There are nearly 30,000 deaths per year in the United States from prostate cancer, making this a large and important target patient population for new cancer treatments.
* SU011248 is an exciting, new, experimental drug that inhibits a number of proteins, or more specifically receptor tyrosine kinases, in tumor cells. These proteins are active in cellular pathways that are important for development and growth of a variety of different cancers. The targets of SU011248 include the receptors for vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and others. By blocking the VEGF and PDGF pathways, SU011248 can induce death of the blood vessels that nourish the cancer cells and death of the cancer cells themselves.
* SU011248 has demonstrated significant anti-tumor activity in renal cell carcinoma, gastrointestinal stromal tumors, and other cancers. Its effect against prostate cancer has not been studied to date.
* This study is directed at two populations of men with advanced prostate cancer:
1. Men with advanced prostate cancer who have a rising PSA despite hormone therapy, but have not yet received any chemotherapy.
2. Men with metastatic prostate cancer who have received prior chemotherapy (with a docetaxel-based regimen) and have increasing disease following chemotherapy.
* Men in this study will receive SU011248 on a six-week repeating schedule, with four weeks of daily treatment followed by a two-week rest. The goals of the study are:
1. to determine whether SU011248 is an important therapeutic agent in men with advanced prostate cancer, and
2. to identify predictive markers of anti-cancer activity within individual subjects that would allow selective treatment of appropriate subjects in the future.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY The Number of Men With Advanced Prostate Cancer Treated With Sunitinib Who Have a Prostate Specific Antigen (PSA) Response |
2 | — |
| SECONDARY Objective Responses, Defined as the Number of Participants With Complete or Partial Response |
1 | — |
Eligibility Criteria
Inclusion Criteria
- Signed informed consent indicating that the subject has been informed of all pertinent aspects of the trial.
- Adenocarcinoma of the prostate
- Male subjects, 18 years of age or older
- Life expectancy of > 12 weeks
- Resolution of all acute toxic effects of prior chemotherapy, radiotherapy or surgical procedure to National Cancer Institute Common Toxicity Criteria Adverse Event (NCI CTCAE) grade 1,500/ul
- Platelet count > 75,000/ul
- Adequate hepatic function:
- Serum bilirubin 5.0 ng/mL, based on PSA Working Group Criteria
- Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests and other study procedures
For Group A only:
· No prior treatment for prostate cancer with cytotoxic chemotherapy
For Group B only:
- Radiographic evidence of metastatic prostate cancer
- One prior docetaxel-based chemotherapy regimen, minimum of two cycles
- Disease progression during treatment with docetaxel, or within 60 days of receiving docetaxel
Exclusion Criteria
- Small cell carcinoma of the prostate
- Treatment with extensive external beam radiation therapy or radionuclide therapy within six weeks of study entry. Palliative radiation involving less than 20% of bone marrow reserves must have been completed within four weeks of entry.
- Any of the following within the prior 6 months: unstable angina, myocardial infarction, symptomatic congestive heart failure or cerebrovascular accident
- Receipt of any investigational anti-cancer agent within 4 weeks of the study
- NCI CTCAE grade 3 hemorrhage 450 msec
- Other serious acute or chronic medical or psychiatric condition that may increase the risk associated with study participation, and in the judgment of the investigator would make the subject inappropriate for entry into this study.
Data sourced from ClinicalTrials.gov (NCT00299741). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.